Lupin Divests U.S. Commercial Women's Health Specialty Business To Evofem Biosciences

RTTNews | 107 days ago
Lupin Divests U.S. Commercial Women's Health Specialty Business To Evofem Biosciences

(RTTNews) - Pharma major Lupin Ltd. announced Monday that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (EVFM), a U.S. biopharmaceutical company focused exclusively on Women's Health.

Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC (secnidazole) 2g oral granules.

This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.

read more
Evofem Biosciences Names Albert Altro As Interim CFO

Evofem Biosciences Names Albert Altro As Interim CFO

Evofem Biosciences, Inc. (EVFM) announced Thursday the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to explore other opportunities.
RTTNews | 601 days ago
Evofem Biosciences Says Vaginal Contraceptive Gel Phexxi Approved  In Nigeria

Evofem Biosciences Says Vaginal Contraceptive Gel Phexxi Approved In Nigeria

Evofem Biosciences, Inc. (EVFM) announced Thursday that its hormone-free contraceptive vaginal gel Phexxi has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and Drug Administration and Control). This is the first regulatory approval outside the U.S.
RTTNews | 755 days ago
Evofem Inks Deal With Pharmacy Benefit Managers In The U.S. For Access To Phexxi

Evofem Inks Deal With Pharmacy Benefit Managers In The U.S. For Access To Phexxi

Evofem Biosciences, Inc. (EVFM) announced Tuesday it has reached an agreement with one of the nation's largest pharmacy benefit managers (PBMs) to ensure most women covered by this plan can fill their Phexxi prescriptions for pregnancy prevention, without restrictions such as prior authorization or step therapy. Phexxi is an on-demand method of birth control used to prevent pregnancy.
RTTNews | 855 days ago
U.S. Pending Home Sales Spike Much More Than Expected In September

U.S. Pending Home Sales Spike Much More Than Expected In September

Pending home sales in the U.S. spiked by much more than expected in the month of September, according to a report released by the National Association of Realtors on Wednesday. NAR said its pending home sales index soared by 7.4 percent to 75.8 in September after climbing by 0.6 percent to 70.6 in August. Economists had expected pending home sales to jump by 1.1 percent.
RTTNews | 6h 51min ago
GSK Q3 Results Down, Sees FY24 Outlook At Mid Range; Stock Drops

GSK Q3 Results Down, Sees FY24 Outlook At Mid Range; Stock Drops

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE after the British drug maker reported Wednesday sharply lower profit in its third quarter on $2.3 billion charge on Zantac settlement, as well as weak revenues. Further, GSK confirmed its fiscal 2024 outlook for earnings, core profit and sales.
RTTNews | 7h 23min ago
U.S. Economic Growth Unexpectedly Slows Modestly In Q3

U.S. Economic Growth Unexpectedly Slows Modestly In Q3

A report released by the Commerce Department on Wednesday showed U.S. economic growth unexpectedly slowed in the third quarter. The Commerce Department said gross domestic product shot up by 2.8 percent in the third quarter after surging by 3.0 percent in the second quarter. Economists had expected another 3.0 percent jump.
RTTNews | 7h 51min ago
Euroarea Logs Faster GDP Growth In Q3 Despite Recession Worries

Euroarea Logs Faster GDP Growth In Q3 Despite Recession Worries

The Eurozone economic growth improved unexpectedly in the third quarter, easing fears of an imminent recession as Germany, France and Spain registered better-than-expected growth. Gross domestic product increased 0.4 percent on a quarterly basis, the preliminary flash estimate from Eurostat showed Wednesday. GDP was expected to log 0.2 percent growth, the same rate as seen in the second quarter.
RTTNews | 7h 53min ago
U.S. Private Sector Employment Surges By 233,000 Jobs In October, Much More Than Expected

U.S. Private Sector Employment Surges By 233,000 Jobs In October, Much More Than Expected

Payroll processor ADP released a report on Wednesday showing private sector employment in the U.S. shot up by much more than anticipated in the month of October. ADP said private sector employment surged by 233,000 jobs in October after jumping by an upwardly revised 159,000 jobs in September. Economists had expected private sector employment to climb by 115,000 jobs.
RTTNews | 8h 24min ago